CH Innovations and Catalytic Impact Foundation invest in DeckTherapeutics

DeckTherapeutics today announced that CH Innovations (CHI) and Catalytic Impact Foundation (CIF) have completed seed investments in the company. CHI and CIF are both committed to improving children’s health, including through investments in early-stage life science companies.

These investments follow the award in July 2022 of a grant from the Bill & Melinda Gates Foundation. This grant enables testing of DeckTherapeutics’ lead compound THDG3 in large animal models of the rare pediatric disease HIE. Furthermore, the highly successful industry veterans Drs. Larry Gold and Yechezkel Barenholz were appointed to DeckTherapeutics’ board of directors in September 2022.
Going forward, John Parker, MBA (CHI) and Richard Lipkin, MBA (CIF) will serve as board observers.